肿瘤血管生成抑制剂临床应用进展  

Current clinical application progress in angiogenesis inhibitors

作　　者：陆宇 

机构地区：[1]南京天易生物科技有限公司,南京210061

出　　处：《上海师范大学学报（自然科学版）》2018年第1期132-138,共7页Journal of Shanghai Normal University(Natural Sciences)

基　　金：江苏省自然科学基金(BK20130106)

摘　　要：血管生成抑制剂已被证明是一类有效的肿瘤治疗药物.概述了从单靶点、多靶点,到广谱血管生成抑制剂在临床上的应用;介绍了单克隆抗体、小分子和内源性的血管生成抑制剂及其相应靶点,讨论了新的靶点及有前景的新型血管生成抑制剂,希望为未来临床治疗提供切实的帮助.Inhibition of angiogenesis is an established modality of cancer treatment. We summarized angiogenesis inhibitors of three modalities： single-target,multi-target and broad-spectrum agents. We discussed the clinical efficacy of monoclonal antibodies,small molecules,endogenous angiogenesis inhibitors and their molecular targets. The promising targets and antiangiogenic treatments were discussed as well. This reviewing article may offer practical help for cancer therapy in the future.

关 键 词：肿瘤 血管生成 血管生成抑制剂 

分 类 号：R730.53[医药卫生—肿瘤]